Insider buying last 90 days
No open-market insider purchases were filed for WST in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
West Pharmaceutical Services' week centers on strong Q3 2026 results and a raised outlook: sales of $874.5 million and net income of $214 million led management to lift full-year net sales guidance to $3.41 billion to $3.42 billion and diluted EPS to $9.31 to $9.41, alongside share repurchases. This built on the prior quarter's beat, where adjusted EPS of $2.37 topped estimates of $2.08. Alongside the raised outlook, commentary has turned to valuation, with separate pieces questioning whether the stock's 54.7% one-year gain is justified by cash flow, with one view suggesting shares could be roughly 29% overvalued on a discounted cash flow basis.
WST closed at $416.42, up 1.2%, sitting above both its 50-day average of $380.17 and 200-day average of $321.39, with the shorter average above the longer one. The GekkoIndex reads 51.8, placing it in the Neutral zone. Against this, Gekko Fair Value stands at $361.23, putting the current price 15.3% above that level.
The next earnings date falls on 11 February 2027, 89 days out and beyond a typical 20-day holding window. No insider, Congress or unusual options activity appears in their respective windows, and a recent filing shows Candriam S.C.A. increasing its stake by 3.3%. Seasonally, the next 20 trading days have averaged a 1.9% gain over 5 years, rising in 4 of them. Analyst coverage from 6 firms is unanimously rated buy, with a consensus target of 471.
Written by AI from the Nov 13, 2026 close and checked automatically against the figures on this page.
West Pharmaceutical Services scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
Above 50 and 200-day
Close $416.42 is above the 50-day ($380.17) and 200-day ($321.39) averages, and the 50-day is above the 200-day.
See the chart51.8, Neutral
Reading 51.8 is in the Neutral zone.
See the GekkoIndex14.7% above
Price is 14.7% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 88 days
Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.
See earnings+1.9% on average
From this point in the calendar, the next 20 trading days averaged +1.9% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
West Pharmaceutical Services closed at $416.42 on Nov 13, 2026, +52.1% over the past year, inside a 52-week range of $223.83 to $438.27.
Use the left and right arrow keys to read daily values.
Put WST on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
West Pharmaceutical Services designs, manufactures, and distributes components used to package and deliver injectable medicines and other healthcare products. It is best known for parts such as stoppers, seals, and syringe and cartridge components that protect and administer injectable drugs, along with devices that support mixing, reconstitution, and self-injection.
The company organizes its work into two units. Its Proprietary Products business supplies packaging components, drug containment materials, self-injection devices, and support services such as lab analysis, packaging assistance, engineering, regulatory help, and technical support, mainly for makers of biologic, generic, and other pharmaceutical products. Its Contract-Manufactured Products business designs and assembles devices for surgical, diagnostic, ophthalmic, and drug delivery use, as well as consumer items, serving pharmaceutical, diagnostic, and medical device manufacturers. Products reach buyers worldwide through its own sales force, distribution network, and outside sales agents and distributors, with operations across the Americas, Europe, the Middle East, Africa, and Asia Pacific.
West Pharmaceutical Services was founded in 1923 and is headquartered in Exton, Pennsylvania. Its shares are listed on the NYSE under the ticker WST.
West Pharmaceutical Services’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.8, in the Neutral zone, down 0.5 points over five sessions.
Down 0.5 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | +2.4% | +4.4% | ||
| Accumulation | 205 | −0.1% | 0.0% | ||
| Neutral (current zone) | 418 | +0.5% | +1.0% | ||
| Distribution | 41 | −1.8% | −2.8% | ||
| Selling | 3 | Too few readings yet | |||
Average WST share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
West Pharmaceutical Services trades 14.7% above Gekko Fair Value of $363.06, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what West Pharmaceutical Services shares are worth, recalculated every trading day.
$363.06
Gekko Fair Value, Nov 14, 2026
14.7% Overvalued
At the end of Aug 2026 the price was 26.9% above the estimate.
No open-market insider purchases were filed for West Pharmaceutical Services, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for WST in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in WST were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
West Pharmaceutical Services has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds WST.
West Pharmaceutical Services reports on Feb 11, 2027, before the open (88 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 11, 2027
Expected before the open, 88 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | $2.37 est $2.08 | $872.3M est $840.0M | −8.4% |
| Apr 23, 2026 | $2.13 est $1.68 | $844.9M est $780.3M | +11.6% |
| Feb 12, 2026 | $2.04 est $1.83 | $805.0M est $794.9M | +1.8% |
| Oct 23, 2025 | $1.96 est $1.68 | $804.3M est $785.7M | +7.4% |
| Jul 24, 2025 | $1.84 est $1.54 | $766.2M est $726.1M | +15.9% |
| Apr 24, 2025 | $1.45 est $1.26 | $698.0M est $713.0M | −1.7% |
| Feb 13, 2025 | $1.82 est $1.71 | $748.8M est $740.5M | −33.4% |
| Oct 24, 2024 | $1.85 est $1.50 | $746.9M est $709.6M | +7.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for West Pharmaceutical Services is $471.00, +13.1% from the last close, from 6 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 6 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 30 | TD Cowen | $500 | +20.1% |
| Oct 30 | Barclays | $500 | +20.1% |
| Oct 30 | Citi | $494 | +18.6% |
| Oct 30 | UBS | $495 | +18.9% |
| Oct 30 | Evercore ISI | $480 | +15.3% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, West Pharmaceutical Services averaged +1.9% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.5% | 3 of 5 |
| Next 10 trading days | −0.7% | 3 of 5 |
| Next 15 trading days | −1.4% | 2 of 5 |
| Next 20 trading days | +1.9% | 4 of 5 |
| Next 30 trading days | +2.2% | 3 of 5 |
For scale, WST’s typical 20-trading-day move in either direction is about 5.5%.
West Pharmaceutical Services’s market cap is $29.01B, with a P/E ratio of 46.2 and revenue of $3.40B over the last twelve months.
Coverage of West Pharmaceutical Services this week reads positive: 2 positive, 1 neutral and 1 negative headlines.
West Pharmaceutical Services’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
West Pharmaceutical Services’s market cap is $29.01B at the Nov 13, 2026 close of $416.42, with 69.66M shares outstanding. The shares trade on a P/E ratio of 46.2.
The consensus analyst 12-month price target for West Pharmaceutical Services is $471.00, +13.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate West Pharmaceutical Services is overvalued: the Nov 13, 2026 close of $416.42 is 14.7% above Gekko Fair Value of $363.06. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
West Pharmaceutical Services is expected to report on Feb 11, 2027, before the market opens (88 days away). Analysts expect earnings of $2.27 per share on revenue of $825.2M. West Pharmaceutical Services beat the earnings estimate in 8 of its last 8 reports, moving 11% on average across the report.
West Pharmaceutical Services’s 52-week high is $438.27 and its 52-week low is $223.83; it closed at $416.42 on Nov 13, 2026, +52.1% over the past year. Over the last five years the shares peaked at $475.00 on Dec 27, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.